William J. Sandborn
University of California, San Diego
Internal medicineSurgeryRandomized controlled trialAdverse effectImmunologyPlaceboColitisVedolizumabCertolizumab pegolInfliximabInflammatory bowel diseaseMaintenance therapyDiseaseCrohn's diseaseAdalimumabUlcerative colitisIn patientClinical trialMedicineGastroenterology
1,586Publications
182H-index
94.8kCitations
Publications 1602
Newest
#1Brian G. Feagan (UWO: University of Western Ontario)H-Index: 115
#2Reena Khanna (UWO: University of Western Ontario)H-Index: 29
Last. Deborah A. Woodworth (Pfizer)H-Index: 6
view all 12 authors...
Background null Endoscopy is routine in trials of ulcerative colitis therapies. null Aim null To investigate agreement between central and local Mayo endoscopic subscore (MES) reads in the OCTAVE programme METHODS: Flexible sigmoidoscopy was performed in tofacitinib induction (OCTAVE Induction 1&2, NCT01465763 and NCT01458951), maintenance (OCTAVE Sustain, NCT01458574) and open-label, long-term extension (OCTAVE Open, NCT01470612) studies. Kappa statistics and Bowker's tests evaluated agreement/...
Source
#1William J. Sandborn (UCSD: University of California, San Diego)H-Index: 182
#2Brian G. Feagan (UWO: University of Western Ontario)H-Index: 115
Last. Ji Hwan Lee (Yale University)
view all 16 authors...
BACKGROUND Ozanimod, a selective sphingosine-1-phosphate receptor modulator, is under investigation for the treatment of inflammatory bowel disease. METHODS We conducted a phase 3, multicenter, randomized, double-blind, placebo-controlled trial of ozanimod as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. In the 10-week induction period, patients in cohort 1 were assigned to receive oral ozanimod hydrochloride at a dose of 1 mg (equivalent to...
1 CitationsSource
#1William J. Sandborn (UCSD: University of California, San Diego)H-Index: 182
#2James D. Lewis (UPenn: University of Pennsylvania)H-Index: 105
Last. Brian G. FeaganH-Index: 115
view all 10 authors...
Background and aims null Patient-reported outcomes are recommended endpoints in Crohn's disease (CD) trials. The association between patient-reported general well-being relative to symptoms of diarrhea and abdominal pain (AP) in patients with moderate-to-severe CD was explored. null Methods null Patients from 3 randomized, placebo-controlled, double-blind adalimumab or upadacitinib studies with average daily very soft/liquid stool frequency (SF) ≥4 and/or AP score ≥2 at baseline were included. U...
Source
#1Nicholas J. Talley (University of Newcastle)H-Index: 183
#2Amol P. KambojH-Index: 2
Last. Anthony Lembo (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 71
view all 18 authors...
Source
#2Cecilia RenzulliH-Index: 5
Last. Guangyong Zou (UWO: University of Western Ontario)H-Index: 44
view all 16 authors...
Background and aims null We aimed to quantify the magnitude of the association between endoscopic recurrence and clinical recurrence [symptom relapse] in patients with postoperative Crohn's disease. null Methods null Databases were searched to October 2, 2020 for randomised controlled trials [RCTs] and cohort studies of adult patients with Crohn's disease with ileocolonic resection and anastomosis. Summary effect estimates for the association between clinical recurrence and endoscopic recurrence...
Source
#1Nghia Nguyen (UCSD: University of California, San Diego)H-Index: 23
#2Dominic Picetti (UCSD: University of California, San Diego)
Last. Siddharth Singh (UCSD: University of California, San Diego)H-Index: 67
view all 8 authors...
Background and aims null There is increasing interest in machine learning-based prediction models in inflammatory bowel diseases (IBD). We synthesized and critically appraised studies comparing machine learning vs. traditional statistical models, using routinely available clinical data for risk prediction in IBD. null Methods null Through a systematic review till January 1, 2021, we identified cohort studies that derived and/or validated machine learning models, based on routinely collected clin...
Source
#1William J. Sandborn (UCSD: University of California, San Diego)H-Index: 182
Last. Geert R. D'Haens (UvA: University of Amsterdam)H-Index: 76
view all 16 authors...
Background & Aims null Oral therapies targeting the integrin α4β7 may offer unique advantages for the treatment of inflammatory bowel disease. We characterized the oral α4β7 antagonist peptide PTG-100 in preclinical models and established safety, pharmacokinetic/pharmacodynamic relationships, and efficacy in a phase 2a trial in patients with ulcerative colitis (UC). null Methods null In vitro studies measured binding properties of PTG-100. Mouse studies measured biomarkers and drug concentration...
Source
#1Geert R. D'Haens (UvA: University of Amsterdam)H-Index: 76
#2Walter Reinisch (Medical University of Vienna)H-Index: 100
Last. Xavier HébuterneH-Index: 70
view all 17 authors...
Background null Patients with Crohn's disease (CD) experience intestinal inflammation. Ontamalimab (SHP647), a fully human immunoglobulin G2 monoclonal antibody against mucosal addressin cell adhesion molecule-1, is a potential novel CD treatment. OPERA II, a multicenter, open-label, phase 2 extension study, assessed the long-term safety and efficacy of ontamalimab in patients with moderate-to-severe CD. null Methods null Patients had completed 12 weeks of blinded treatment (placebo or ontamalim...
Source
#1Severine Vermeire (Katholieke Universiteit Leuven)H-Index: 146
#2Geert R. D'Haens (UvA: University of Amsterdam)H-Index: 76
Last. Chunlin Chen (Millennium Pharmaceuticals)
view all 13 authors...
Background and aims null Report results from VISIBLE 2, a randomised, double-blind, placebo-controlled phase 3 trial evaluating a new subcutaneous [SC] vedolizumab formulation as maintenance treatment in adults with moderately to severely active Crohn's disease [CD]. null Methods null Following open-label vedolizumab 300 mg intravenous induction therapy at Weeks 0 and 2, Week 6 clinical responders (≥70-point decrease in CD Activity Index [CDAI] score from baseline) were randomised 2:1 to receive...
Source
#1Bo Shen (NewYork–Presbyterian Hospital)H-Index: 69
#2Gursimran Kochhar (Allegheny Health Network)H-Index: 18
Last. Jason Schairer (HFHS: Henry Ford Health System)H-Index: 1
view all 37 authors...
Restorative proctocolectomy with ileal pouch-anal anastomosis is an option for most patients with ulcerative colitis or familial adenomatous polyposis who require colectomy. Although the construction of an ileal pouch substantially improves patients' health-related quality of life, the surgery is, directly or indirectly, associated with various structural, inflammatory, and functional adverse sequelae. Furthermore, the surgical procedure does not completely abolish the risk for neoplasia. Patien...
Source